Dan

BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer

Industry veteran brings nearly 20 years of broad leadership experience in biopharma PITTSBURGH, PA, October 04, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, announced the appointment of Keir Loiacono, Esq. to Chief Executive […]

BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer Read More »

BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit

Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs PITTSBURGH, Sept. 26, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today

BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit Read More »

BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit

PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the company will present a poster, at the 7th Annual CAR-TCR Summit, being held in Boston, MA from September 19 –

BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit Read More »

BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat

PITTSBURGH, PA, May 25, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Sawa Ito, M.D., Ph.D., was selected to provide an oral presentation during the 2022 Joint ASTCT + EBMT Basic

BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat Read More »